RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that the U.S. Patent and Trademark Office recently issued U.S. Patent No. 11,576,911.
This patent, issued to Glytech LLC, is exclusively licensed to NeuroRx, Inc., a wholly owned subsidiary of NRx, under the terms of a license agreement with Glytech through which NeuroRx has the sole rights to this and other patents, both U.S. and international. The licensed patents cover certain pharmaceutical formulations and their uses in treating a variety of neuropsychiatric conditions, including bipolar depression, major depressive disorder, PTSD, and suicidality.
In particular, the claims of the new patent cover methods for treating a patient suffering from depression, including bipolar depression or major depression, with or without suicidality by administering to the patient an effective amount of the Company’s lead product candidate, NRX-101. Should this drug candidate be approved by the U.S. Food & Drug Administration, this newly issued patent is expected to be listable in the FDA’s “Orange Book” for NRX-101, which is currently undergoing clinical trials in the U.S. The ‘patent represents the U.S. version of a third patent family owned by or exclusively licensed to NeuroRx that covers the NRX-101 formulation or its methods of use in treating depressive disorders, and such patent coverage is expected to remain in force through at least July 2033 prior to any patent term extensions available under federal law. Previously issued patents cover the NRX-101 composition of matter and methods for preventing akathisia, a common side effect of SSRI antidepressants.
“The grant of this new patent augments the strength of NRx Pharmaceuticals’ intellectual property, which consists of about 90 patents and patent applications globally,” said Stephen Willard, Chief Executive Officer of NRx Pharmaceuticals. “It validates the novelty or our science and highlights its potential importance in bringing lifesaving treatments to patients with life-threatening neuropsychiatric conditions, including depression and PTSD.”
In 2023, the company expects to have additional patents granted from its pending portfolio and to file more patent applications in the U.S. and internationally.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.
Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.